Monkeypox Vaccine And Treatment Market Companies
- Bavarian Nordic
- Emergent BioSolutions
- Johnson & Johnson
- Moderna
- Novavax
- CanSino BioPharma
- Gamaleya Research Institute
- Bharat Biotech
- Serum Institute of India
- Takeda
- Sanofi Pasteur
- GSK
- Merck
- Pfizer
- BioNTech
Recent News:
- WHO declares Monkeypox a public health emergency international in August 2022; the declaration of monkeypox as a PHEIC by WHO was a game changer in the world's direction in the fight against the virus. The statement gave leverage to increased funding for international cooperation and actualized vaccine research. Following this declaration, more dynamic vaccination campaigns followed from most governments and health bodies to combat this pandemic, especially in high-risk areas. The declaration also pushed pharmaceutical companies into fast-tracking R&D processes around vaccine candidates.
- U.S. CDC Expands Monkeypox Vaccination Guidelines In January 2023, the CDC revised its recommendations, extending the need for vaccination for monkeypox to include some high-risk groups. This step was based on the persistence of the virus's spread on American soil and thus turned into a widely imperative call to protect vulnerable populations. The new guidelines contributed to more vaccine availability and distribution, particularly in areas hard hit by outbreaks. But this came with public health campaigns to urge vaccination amongst the newly eligible groups.